Loading...
Loading...
Skyhawk Therapeutics is seeking an Associate Director, Regulatory Affairs CMC to support the global strategy for their small molecule pipeline. This role involves partnering with various departments to ensure timely and high-quality regulatory submissions for clinical development and commercialization. The ideal candidate is a growing RegCMC professional who thrives in a fast-paced, science-driven biotech environment and can make a visible impact.
Associate Director, Regulatory Affairs CMC
Skyhawk Therapeutics is seeking a hands-on, Associate Director, Regulatory Affairs CMC (RegCMC) to support the development and execution of the global RegCMC strategy for Skyhawk's small molecule pipeline. Working closely with the Director, RegCMC, you will help serve as a RegCMC point of contact across the organization, partnering with Pharmaceutical Development, Manufacturing, Quality, and Program teams to deliver high-quality, timely regulatory submissions that advance clinical development and support eventual commercialization. This is an ideal opportunity for a growing RegCMC professional who thrives in fast-paced, science-driven biotech where their work has direct and visible impact.
Responsibilities:
Education/Skills/Experience Requirements:
Preferred Qualifications
Skyhawk Therapeutics is committed to pay transparency and equitable compensation practices. The base salary range for the Clinical Trial Associate is $170,000-230,000 annually. This range reflects the minimum and maximum target for such position. Skyhawk Therapeutics will assess the appropriate level for a qualified candidate based on job-related skills, professional experience, and relevant education or training.
About Skyhawk
Skyhawk is committed to discovering, developing and commercializing small molecule therapeutics that modify RNA expression. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed toward targets for some of the world’s most intractable diseases including neurological conditions, cancer, and traditionally “undruggable” targets.